MedTrace Logo

Economic Analysis of Alliance A041202 CLL Study

NCT02414022 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 55

Last updated 2026-05-08

No results posted yet for this study

Summary

The prospective cost-effectiveness (cost-utility) analysis from the perspective of the Canadian public healthcare system was completed in 2021. Health state utilities were collected using the EuroQOL EQ-5D instrument with Canadian tarrifs applied to calculate quality-adjusted life-years (QALYs). Costs were applied to resource utilization data (expressed in 20196 US dollars). We examined costs and outcomes (QALYs) associated with ibrutinib with rituximab (IR) and BR therapy.

Conditions

Sponsors & Collaborators

  • Canadian Cancer Trials Group

    lead NETWORK

Principal Investigators

  • Matthew Cheung · Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto ON Canada

Eligibility

Min Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-04-15
Primary Completion
2019-04-05
Completion
2026-06-07

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02414022 on ClinicalTrials.gov